- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02895659
Fluid Management in Patients Undergoing Cardiac Surgery (Hemacetat)
Fluid Management in Patients Undergoing Cardiac Surgery - Effects of an Acetate Versus Lactate Buffered Balanced Infusion Solution on Hemodynamic Stability, a Randomized Controlled Double-blind Trial
Background: Currently used crystalloid solutes have a variable composition and may therefore influence acid-base status, intra- and extracellular water content and plasma electrolyte compositions and have a major impact on organ function and outcome. Despite continuing evaluation no superiority of one particular type of fluid has been reached so far. To the best of the investigators' knowledge no study in humans has ever assessed whether the type of crystalloid fluid given for fluid resuscitation in patients undergoing cardiac surgery has an impact on hemodynamic stability and cardiac function so far. Nonetheless in the animal model it was shown that the choice of crystalloid fluid may greatly influence cardiac performance
Primary Aim: In this study the investigators want to clarify whether a balanced type acetate-buffered fluid solution in patients undergoing cardiac surgery is associated with better hemodynamic stability and cardiac function than a lactate-buffered crystalloid solute.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Bern, Suíça, 3010
- Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Elective single heart valve replacement
- Elective double valve replacement
- Elective single or double valve replacement and coronary artery bypass grafting
Exclusion Criteria:
- Patients unable to give informed consent
- Patients younger than 18 years of age or older than 80 years
- Pregnancy or breastfeeding
- Ejection fraction (EF) of less than 30% preoperatively
- Preexisting renal insufficiency with a glomerular filtration rate below 30ml/min
- Patients transferred form the intensive care unit to the operating theater
- Emergency operation
- Reoperation
- Patients planned for fast-track surgery
- Patients planned for minimal extracorporal circuits
- Preexisting anemia requiring immediate perioperative blood transfusion
- Chronic inflammatory diseases
- Any signs of infection or sepsis
- Limitation of full therapy (e.g. Jehowa's witnesses)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Ringer lactate
Fluid resuscitation will be performed with lactated Ringers during the perioperative period.
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
|
Comparador Ativo: Ringer acetate
Fluid resuscitation will be performed with acetated Ringers during the perioperative period.
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
Perioperative hemodynamic management will be performed according to a specified treatment protocol.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Cumulative dose of inopressors (norepinephrine and epinephrine) per kg bodyweight/hour during the perioperative period
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Time on inopressors
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
|
Cumulative dose of inodilators
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
|
Time on inodilators
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
|
Cumulative dose of vasodilatators
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
|
Time on vasodilatators
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
|
Total amount of fluid
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
|
Changes in acid-base status
Prazo: Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Perioperative period (induction of anesthesia until extubation in the intensive care unit, usually less than 24 hours))
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Carmen A Pfortmueller, MD, Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Atributos da doença
- Doença grave
- Efeitos Fisiológicos das Drogas
- Agentes Adrenérgicos
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Alfa-Agonistas Adrenérgicos
- Agonistas Adrenérgicos
- Agentes broncodilatadores
- Agentes Antiasmáticos
- Agentes do Sistema Respiratório
- Beta-Agonistas Adrenérgicos
- Simpaticomiméticos
- Agentes vasoconstritores
- Midriáticos
- Noradrenalina
- Epinefrina
- Racepinefrina
- Borato de epinefril
Outros números de identificação do estudo
- 20160804.1.3
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .